KCG
IBB icon

Knight Capital Group’s iShares Biotechnology ETF IBB Stock Holding History

Knight Capital Group’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q2 		$614K Buy
+10,611
New +$613K 0.01% 1508

Other funds holding IBB

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
CM
Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return
Bank of Nova Scotia
Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Knight Capital Group's IBB Position: Q2 2013 in Review

Knight Capital Group opened a new position in iShares Biotechnology ETF (IBB) in Q2 2013: 10,611 shares worth $614K. The stake represents 0.01% of the portfolio and ranks #1508 among its holdings.

232 funds tracked by Wall St. Rank hold IBB as of Q2 2013.

  • Knight Capital Group held 10,611 shares of iShares Biotechnology ETF worth $614K as of Q2 2013.
  • iShares Biotechnology ETF was a new Knight Capital Group position in Q2 2013.
  • iShares Biotechnology ETF made up 0.01% of Knight Capital Group's portfolio in Q2 2013, its #1508 holding.
  • 232 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.